ARYx Therapeutics
Pioneering new standards in oral therapies for chronic diseases with advanced retrometabolic drug design expertise.
Pioneering new standards in oral therapies for chronic diseases with advanced retrometabolic drug design expertise.
ARYx Therapeutics is a pioneering pharmaceutical company specializing in retrometabolic drug design. Founded in 1997, the company is focused on revolutionizing oral therapies for chronic diseases. ARYx has garnered significant attention within the Biotechnology, Health and Wellness, and Pharmaceutical industries. The company has attracted substantial investments, with the last recorded investment amounting to $6.30M, a post-IPO debt investment made on 16 August 2010. The investor behind this significant backing was Lighthouse Capital Partners. ARYx Therapeutics is undeniably at the forefront of advancing retrometabolic drug design, and their innovative approach to improving the safety of oral therapies for chronic diseases positions them as a key player in the pharmaceutical landscape.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Debt | $6.30M | 1 | Lighthouse Capital Partners | 16 Aug 2010 |
| Post-IPO Equity | $357.45K | - | 13 Nov 2009 | |
| Post-IPO Equity | $21.60M | 3 |
|
12 Nov 2008 |
| Series E | $30.40M | 9 |
|
10 Feb 2006 |
| Series D | $55.00M | 9 |
|
01 Jun 2004 |
No recent news or press coverage available for ARYx Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
